GINS表达水平与肿瘤患者预后关系的meta分析  

Meta-analysis of the Relationship between the Expression Level of GINS and the Prognosis of Tumor Patients

作　　者：王世博[1] 柳晓金[2] 郑立恒[3] 高艳军[3] WANG Shibo(The Second Hospital of Hebei Medical University,Hebei Shijiazhuang 050000,China)

机构地区：[1]河北医科大学第二医院感染控制处,河北石家庄050000 [2]河北省石家庄市第五医院感染科,河北石家庄050041 [3]河北省胸科医院检验科,河北石家庄050041

出　　处：《河北医学》2020年第1期80-83,共4页Hebei Medicine

基　　金：河北省医学科学研究重点课题计划项目,(编号:20150602)

摘　　要：目的: 应用meta分析评价DNA复制复合体(GINS)表达水平与肿瘤患者预后的关系。 方法: 检索万方医学网,维普数据库,PubMed数据库中关于GINS表达水平与肿瘤患者预后关系的相关文章,检索时间截止到2019年4月30日,采用revman5.3软件进行meta分析。 结果: 纳入的7篇报道了GINS基因表达水平与总生存期(OS)的关系,病例数为854例,结果显示高表达GINS基因的肿瘤患者OS显著缩短(HR=2.11,95%CI为1.43~3.10,P=0.0002);纳入3篇报道了GINS基因表达水平与无病生存期(DFS)的关系,病例数为991例,结果显示高表达GINS基因的肿瘤患者DFS显著缩短(HR=1.60,95%CI为1.38~1.86,P=0.00001)。 结论: GINS基因高表达与肿瘤患者的不良预后有一定的关系,提示GINS可能成为肿瘤预后潜在靶标。Objective: To evaluate the relationship between GINS expression levels and the prognosis of tumor patients used by meta-analysis. Methods: The articles about the relationship between the expression level of GINS and the prognosis of cancer patients in Wanfang medical network, VIP database and PubMed database were retrieved. The retrieval time was up to April 30, 2019, and the meta-analysis was carried out with Revman 5.3 software. Results: 7 articles including 722 patients included in the study about the relationship between GINS gene expression levels and overall survival (OS), the results showed high GINS gene expression of tumor patients significantly shortened OS (HR = 2.11, 95% CI 1.43 ~ 3.10, P = 0.0002);3 articles including 991 patients included in the study about the relationship between GINS gene expression levels and disease-free survival (DFS), the results showed high GINS gene expression of tumor patients significantly shortened DFS (HR = 1.60, 95% CI 1.38 ~ 1.86, P = 0.00001). Conclusion: The high expression of GINS gene has a certain relationship with the poor prognosis of tumor patients, suggesting that GINS may be a potential target for tumor prognosis.

关 键 词：GINS 肿瘤 META分析 预后 

分 类 号：R730[医药卫生—肿瘤]